Skip to main content
Move the World.
Blood Test for Cancer

Lead Image © Science Photo / Adobe Stock

A University of Cambridge-led research team has unveiled a personalized blood test for cancer monitoring that can find one molecule of tumor DNA in a sample containing more than a million DNA molecules — a sensitivity up to 10 times greater than existing methods.

This technique could one day speed up the detection of a cancer relapse or let doctors know more quickly if a treatment wasn't effective. Eventually, it could even support the creation of an at-home blood test for cancer that patients could self-administer.

A Blood Test for Cancer

Over the past decade, doctors have started relying more and more on a technique called a "liquid biopsy" when treating cancer patients.

While standard biopsies involve the invasive extraction of a tissue sample from a patient, a liquid biopsy only requires drawing their blood. The doctor can then analyze the blood for cancer biomarkers.

"This is like detecting a needle in the haystack."

Jonathan Wan

One of the most common of those biomarkers — and the one at the center of this new study — is circulating, cell-free tumour DNA (ctDNA): small pieces of genetic material that tumors shed into the bloodstream.

ctDNA contains mutations not found in a patient's own DNA, so doctors can use genetic analysis technology to hunt for those mutated molecules in the patient's blood — if they find them, they'll know a patient still has cancer, without subjecting them to an invasive procedure.

The problem is the sensitivity of current liquid biopsy techniques — they're typically designed to look for 10 to 20 mutations and, from a test tube of blood, might spot one mutant piece of DNA among 30,000 molecules.

"(I)n patients with small tumors or after complete resection of their tumor using surgery, the concentration of cancer DNA in the blood can be low and can be challenging to detect," researcher Jonathan Wan explained in a video. "This is like detecting a needle in the haystack."

A New Liquid Biopsy Technique

To improve upon this type of blood test for cancer monitoring, the Cambridge team sequenced both a patient's tumor to identify hundreds or even thousands of mutations they could then look for in a blood sample.

Essentially, they dramatically increased the number of potential needles that are available to find in the haystack.

They then combined this increased number of targets with methods to enhance the signal of the mutations and dubbed their finished approach the Integration of VAriant Reads (INVAR) pipeline.

When they used INVAR to analyze samples from 105 patients, with five different types of cancers in various stages, they found it could regularly detect one mutant molecule in 100,000 pieces of DNA.

In some cases, the technique could even find one cancer molecule within a million pieces of DNA, according to the study the researchers published in Science Translational Medicine.

The team believes the methods they developed for INVAR could eventually decrease the size of the sample required to effectively detect ctDNA, too, shrinking the size of the haystack, as well as increasing the number of needles in it.

One day, they claim in a press release, INVAR could even lead to the creation of a pinprick home blood test for cancer, giving cancer survivors the ability to routinely monitor themselves for signs of relapse. (But given the history of such claims, it's probably best to wait for more evidence before celebrating.)

"At present this is still experimental, but technology is advancing rapidly, and in the near future tests with such sensitivity could make a real difference to patients," lead researcher Nitzan Rosenfeld said.

We'd love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Up Next

Why Advanced Cancer Patients Need Genetic Sequencing
Why Advanced Cancer Patients Need Genetic Sequencing
Watch Now
Why Advanced Cancer Patients Need Genetic Sequencing
Genomic sequencing saved his life. Now he wants everyone to have access.
Watch Now

After he was diagnosed with life-threatening prostate cancer, Intel’s Bryce Olson sequenced his genome which offered clues to new treatments for his disease. While the current standard of care for cancer patients includes surgery, radiation, and chemotherapy, genetic sequencing opens the door for new possibilities beyond these traditional approaches. Bryce explains his personal mission to encourage others to get their...

Making Tumors Glow to Improve Cancer Surgery
Making Tumors Glow to Improve Cancer Surgery
Watch Now
Making Tumors Glow to Improve Cancer Surgery
This surgeon is improving surgery by lighting up cancer cells.
Watch Now

This surgeon, Dr. Sunil Singhal, is making tumors glow to help doctors ensure they have removed all of the cancer cells at the surgery site. Completely removing cancer tumors can be difficult, and if a small amount remains, the cancer can recur. Sunil, the director of the Thoracic Surgery Research Laboratory at the University of Pennsylvania, came up with the idea of using glowing tumors to advance cancer surgery after an...

Intel
The Future of Cancer Research
The Future of Cancer Research
Watch Now
Intel
The Future of Cancer Research
Intel's Bryce Olson used genomic sequencing to help fight his cancer. Now he’s helping researchers use artificial intelligence to discover entirely new cancer treatments.
Watch Now

Intel employee Bryce Olson was diagnosed with stage 4 prostate cancer. When the standard of care didn’t work, Bryce turned to genomic sequencing which allowed his doctors to identify specific genetic drivers of his disease and specific treatments and clinical trials that were a fit for his cancer. This precision medicine approach helped send his cancer into remission for several years. Now that his cancer has returned,...

Dispatches
23andMe Can (Finally) Tell You about Your Genetic Cancer Risk
23andMe Can (Finally) Tell You about Your Genetic Cancer Risk
Dispatches
23andMe Can (Finally) Tell You about Your Genetic Cancer Risk
23andMe has won the right to tell you what your genes say about you. It's a landmark legal achievement that could...

23andMe has won the right to tell you what your genes say about you. It's a landmark legal achievement that could help usher in a new age of personalized medicine.

Health
“Electronic Nose” Can Detect a Cancer Precursor on Patients’ Breath
electronic nose
Health
“Electronic Nose” Can Detect a Cancer Precursor on Patients’ Breath
A new study found that an electronic nose could be an improved screening tool for Barrett’s esophagus, a precursor to esophageal cancer.

A new study found that an electronic nose could be an improved screening tool for Barrett’s esophagus, a precursor to esophageal cancer.

INTEL
Why Cancer Patients Should Get Genetic Sequencing
Why Cancer Patients Should Get Genetic Sequencing
Watch Now
INTEL
Why Cancer Patients Should Get Genetic Sequencing
Genomic sequencing saved his live. Now he wants everyone to have access.
Watch Now

After he was diagnosed with life-threatening prostate cancer, Intel’s Bryce Olson sequenced his genome which offered clues to new treatments for his disease. While the current standard of care for cancer patients includes surgery, radiation, and chemotherapy, genetic sequencing opens the door for new possibilities beyond these traditional approaches. Bryce explains his personal mission to encourage others to get their...

Genetics
Genetic “Off Switch” May Lead to New Breast Cancer Treatment
Breast Cancer Treatment
Genetics
Genetic “Off Switch” May Lead to New Breast Cancer Treatment
A much-needed triple negative breast cancer treatment could center on the suppression of a single gene identified in a new Tulane University study.

A much-needed triple negative breast cancer treatment could center on the suppression of a single gene identified in a new Tulane University study.

Future of Medicine
Using Artificial Intelligence to Improve Breast Cancer Screening
Scientists Are Using AI to Improve Breast Cancer Screening
Future of Medicine
Using Artificial Intelligence to Improve Breast Cancer Screening
Computer scientists at MIT created a new algorithm for breast cancer screening to predict whether a patient will develop the disease in the next 5 years.

Computer scientists at MIT created a new algorithm for breast cancer screening to predict whether a patient will develop the disease in the next 5 years.

Uprising
What's Special About Cancer-Killing Nanobots? Precision.
medical nanobots
Uprising
What's Special About Cancer-Killing Nanobots? Precision.
These tiny, robotic machines can deliver drugs directly to infected cells, and they're changing the future of medicine.

These tiny, robotic machines can deliver drugs directly to infected cells, and they're changing the future of medicine.